论文部分内容阅读
目的:观察苦参素辅助治疗乙型病毒性肝炎(HBV)相关原发性肝癌(PHC)临床疗效和安全性。方法:54例HBV相关PHC患者分为对照组和治疗组,2组均行肝动脉化疗栓塞术(TACE),治疗组加服苦参素片共6个月(2个疗程),比较2组治疗前后实体瘤近期疗效、患者生存质量、免疫功能变化、肝功能变化以及安全性指标。结果:与对照组相比,治疗组有效率明显升高(P<0.01),KPS评分升高、稳定例数增加(P<0.05),治疗后CD3+、CD4+、CD4+/CD8+比值及NK细胞活性显著性提高(P<0.05,P<0.01),Child-Pugh评分、ALT含量、HBV DNA均明显降低(P<0.05,P<0.01),发生恶心呕吐、发热、疼痛、WBC下降等不良反应的例数较少(P<0.01)。结论:苦参素可提高TACE的治疗效果并降低不良反应。
Objective: To observe the clinical efficacy and safety of oxymatrine in the treatment of hepatocellular carcinoma (PHC) associated with hepatitis B virus (HBV). Methods: Totally 54 patients with HBV-related PHC were divided into control group and treatment group. Both groups received transcatheter arterial chemoembolization (TACE) for 6 months. Patients in the treatment group received oxymatrine for 6 months (2 cycles) The treatment effect of solid tumor before and after treatment, patient quality of life, immune function changes, changes in liver function and safety indicators. Results: Compared with the control group, the effective rate of the treatment group was significantly increased (P <0.01), KPS score was increased, the number of stable cases was increased (P <0.05), the ratio of CD3 +, CD4 +, CD4 + / CD8 + and NK cell activity (P <0.05, P <0.01), Child-Pugh score, ALT content and HBV DNA were significantly lower (P <0.05, P <0.01), and nausea and vomiting, fever, pain, WBC decline and other adverse reactions Fewer cases (P <0.01). Conclusion: Oxymatrine can improve the therapeutic effect of TACE and reduce adverse reactions.